Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Part of paid clinical trials in Long Beach, California.
- Sponsor
- Gilead Sciences
- Study ID
- NCT02258529
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Follicular Lymphoma
- Small Lymphocytic Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Idelalisib — DRUG150 tablets administered orally twice daily
- Rituximab — BIOLOGICAL375 mg/m\^2 administered intravenously (weekly for 4 weeks and then every 8 weeks from Week 12 up to Week 100)
Study Details
The primary objective of this study is to evaluate the overall response rate (ORR) and complete response (CR) rate to treatment with idelalisib in combination with rituximab in previously untreated adults with follicular lymphoma (FL) or small lymphocytic lymphoma (SLL). An increased rate of deaths and serious adverse events (SAEs) among participants with front-line chronic lymphocytic leukemia (CLL) and early-line indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated those studies in agreement with the DMC recommendation and in consultation with the US Food and Drug Administration (FDA). All front-line studies of idelalisib, including this study, were also terminated.
Key Dates
- Start date
- Sep 14, 2015
- Status verified
- Apr 2017
- Primary completion
- Apr 12, 2016
- Completion
- May 3, 2016
Study Design
- Enrollment
- 10 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Idelalisib + rituximabIdelalisib + rituximab for up to 104 weeks
Primary Outcome Measure
Overall Response Rate
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Pacific Shores Medical Group | Long Beach | California | 90813 | - |
| Florida Cancer Specialists | Fort Myers | Florida | 33916 | - |
| St. Agnes Hospital | Baltimore | Maryland | 21229 | - |
| Prarie Lakes Health Care Systems, Inc. | Watertown | South Dakota | 57201 | - |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | - |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | - |
Find similar trials in Long Beach, CA
Related Studies
- Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)Recruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- Clonal Evolution in Follicular LymphomaRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama